Gilead Sciences' Next-Generation HIV Drug Hits the Mark

Gilead Sciences (GILD) got what it wanted and maybe more from the two Phase III studies of its next-generation HIV drug TAF.

I previewed the importance of TAF to GIlead as a superior replacement to its stalwart but patent-challenged HIV drug Viread on Monday. This morning, the company announced positive results with the TAF-containing regimen (Stribild-TAF) demonstrating statistical non-inferiority to Stribild on the primary endpoint of HIV viral load reduction. 

Better yet, TAF came out superior on two key safety endpoints measuring kidney function and bone mineral density compared to Viread. 

Based on the data from the two studies, Gilead intends to seek regulatory approval for TAF in the U.S. and Europe during the fourth quarter. 

Gilead shares were up about 1.5% to $106.95 in Wednesday trading. The stock's performance this year has been phenomenal, up 42% for the year to date and over 70% for the past 52 weeks.

GILD Chart

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer